Search

Derek Cerchione and colleagues at Editas Medicine in Cambridge have developed a new M13 phage-based directed-evolution strategy and a mutagenesis method called SMOOT to engineer Cas9 nuclease activity. They report the isolation of a Cas9 mu

Derek Cerchione and colleagues at Editas Medicine in Cambridge have developed a new M13 phage-based directed-evolution strategy and a mutagenesis method called SMOOT to engineer Cas9 nuclease activity. They report the isolation of a Cas9 mu

Daniel Lauster (Freie Universität Berlin) and colleagues published a Nature Nanotechnology paper showing their use of phage capsid nanoparticles to block influenza virus entry into cells, leading to inhibition of infection in vitro and in v

BiomX announced positive results from its Phase 1 randomized, double-blind, placebo-controlled cosmetic clinical study in 75 subjects with mild to moderate acne. Their phage product (a topical gel comprised of a cocktail of naturally-occurr

Amit Vikram (Intralytix, Inc) and colleagues published a paper showing that their company's EcoShield phage cocktail reduces E. coli O157:H7 levels by 97% in eight types of foods (including meats, fish, cheese and lettuce), including reduci

A couple of phage therapy podcasts for you this week: one with John Haverty, who received phages from Adaptive Phage Therapeutics to prevent amputation of his leg in 2019. Another with Alexander Belcredi, CEO of PhagoMed.

BiomX announced positive results from its Phase 1 randomized, double-blind, placebo-controlled cosmetic clinical study in 75 subjects with mild to moderate acne. Their phage product (a topical gel comprised of a cocktail of naturally-occurr

A couple of phage therapy podcasts for you this week: one with John Haverty, who received phages from Adaptive Phage Therapeutics to prevent amputation of his leg in 2019. Another with Alexander Belcredi, CEO of PhagoMed.

Daniel Lauster (Freie Universität Berlin) and colleagues published a Nature Nanotechnology paper showing their use of phage capsid nanoparticles to block influenza virus entry into cells, leading to inhibition of infection in vitro and in v

Amit Vikram (Intralytix, Inc) and colleagues published a paper showing that their company's EcoShield phage cocktail reduces E. coli O157:H7 levels by 97% in eight types of foods (including meats, fish, cheese and lettuce), including reduci

Adaptive Phage Therapeutics (APT), having recently doubled its biologics manufacturing capability (intended for its upcoming phage clinical trials), is currently in talks with a partner to help with rapid production of a COVID-19 vaccine ca

Adaptive Phage Therapeutics (APT), having recently doubled its biologics manufacturing capability (intended for its upcoming phage clinical trials), is currently in talks with a partner to help with rapid production of a COVID-19 vaccine ca

Przemysław Decewicz (University of Warsaw, Poland) and colleagues have isolated two virulent phages infecting Ochrobactrum spp. for the first time. The host, due to its extensive repertoire of enzymatic properties, is a key player in the bi

Przemysław Decewicz (University of Warsaw, Poland) and colleagues have isolated two virulent phages infecting Ochrobactrum spp. for the first time. The host, due to its extensive repertoire of enzymatic properties, is a key player in the bi

SciPhage is a women-led biotech company out of Colombia aiming to bring science into society and to support female scientists who want to start a biotech business. To get their Salmonella phage cocktail to market, they have announced a fund

We've seen Adaptive Phage Therapeutics (APT) in the news a lot lately—here's an interview with Greg Merril, APT's CEO, a podcast interview with a patient whose leg was saved by APT's phages, and a news article on APT's selection for Startup

Armata Pharmaceuticals and Innoviva have announced a $25 Million investment to support Armata's phage cocktail development.

BiomX announces dual listing on the Tel-Aviv stock exchange.

SciPhage is a women-led biotech company out of Colombia aiming to bring science into society and to support female scientists who want to start a biotech business. To get their Salmonella phage cocktail to market, they have announced a fund

BiomX announces dual listing on the Tel-Aviv stock exchange.